Peijia Medical (HKG:9996) forecasts its 2024 revenue to surge by 38% to 43% year-over-year to between 610 million yuan and 630 million yuan.
The surge is attributable to growth in the medical equipment company's neuro-interventional product lines and a greater share in the Chinese transcatheter aortic valve replacement market, according to a Monday filing with the Hong Kong Exchange.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。